Absorption Enhancer and Polymer (Vitamin E TPGS and PVP K29) by Solid Dispersion Improve Dissolution and Bioavailability of Eprosartan Mesylate

被引:8
作者
Ahn, Jae Soon [2 ]
Kim, Kang Min [3 ]
Ko, Chan Young [4 ]
Kang, Jae Seon [1 ]
机构
[1] Kyungsung Univ, Dept Pharm, Pusan 608736, South Korea
[2] Kyung Hee Univ, Dept Pharm, Seoul 130701, South Korea
[3] Hyundai Pharm, Ctr R&D, Seoul 153023, South Korea
[4] Sungkyunkwan Univ, Dept Pharm, Suwon 440746, South Korea
关键词
Eprosartan mesylate; Solid dispersion; Vitamin E TPGS; PVP K29; Bioavailability; HOT-MELT EXTRUSION; HUMAN PLASMA; PERCUTANEOUS-ABSORPTION; LC-MS/MS; KETOPROFEN; AMBROXOL; TABLETS; MENTHOL;
D O I
10.5012/bkcs.2011.32.5.1587
中图分类号
O6 [化学];
学科分类号
070301 [无机化学];
摘要
The aim of the present study was to improve the solubility and bioavailability of a poorly water-soluble drug in human body, using a solid dispersion technique (hot melt extrusion). The solid dispersion was prepared by cooling the hot melt of the drug in the carrier (Vitamin E TPGS and PVP). The dissolution rate of formulation 1 from a novel formulation prepared by solid dispersion technique was equal to release of formulation 6 (40% of eprosartan mesylate is in contrast to teveten (R)) within 60 min (Table 1). The oral bioavailability of new eprosartan mesylate tablet having vitamin E TPGS and PVP K29 was tested on rats and dogs. Of the absorption enhancer and polymer tested, vitamin E TPGS and PVP K29, resulted in the greatest increases of AUC in animals (about 2.5-fold increase in rat and dog). When eprosartan mesylate was mixed with the absorption enhancer and polymer in a ratio of 2.94:2:1, vitamin E TPGS and PVP K29 improved eprosartan mesylate bioavailability significantly compared with the conventional immediate release (IR) tablet Teveten (R) (formulation 7). These results show that solid dispersion using vitamin E TPGS and PVP K29 is a promising approach for developing eprosartan mesylate drug products.
引用
收藏
页码:1587 / 1592
页数:6
相关论文
共 19 条
[1]
A dose proportionality study of eprosartan in healthy male volunteers [J].
Chapelsky, MC ;
Martin, DE ;
Tenero, DM ;
Ilson, BE ;
Boike, SC ;
Etheredge, R ;
Jorkasky, DK .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (01) :34-39
[2]
Ching C. C., 2006, PCT patent, Patent No. 052461
[3]
PHARMACEUTICAL APPLICATIONS OF SOLID DISPERSION SYSTEMS [J].
CHIOU, WL ;
RIEGELMAN, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (09) :1281-+
[4]
Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution [J].
Chokshi, RJ ;
Sandhu, HK ;
Iyer, RM ;
Shah, NH ;
Malick, AW ;
Zia, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (11) :2463-2474
[5]
Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical. efflux transporters in Caco-2 cell monolayers [J].
Collnot, EM ;
Baldes, C ;
Wempe, MF ;
Hyatt, J ;
Navarro, L ;
Edgar, KJ ;
Schaefer, UF ;
Lehr, CM .
JOURNAL OF CONTROLLED RELEASE, 2006, 111 (1-2) :35-40
[6]
HEDNER T, 1997, AM J HYPERTENS, V10, pA119
[7]
Determination of ambroxol in human plasma using LC-MS/MS [J].
Kim, H ;
Yoo, JY ;
Han, SB ;
Lee, HJ ;
Lee, KR .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 32 (02) :209-216
[8]
Improving drug solubility for oral delivery using solid dispersions [J].
Leuner, C ;
Dressman, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) :47-60
[9]
Promoting mechanism of menthol derivative, 1-O-ethyl-3-buthylcyclohexanol, on the percutaneous absorption of ketoprofen [J].
Li, CJ ;
HigashIyama, K ;
Yoshimura, Y ;
Nagai, T ;
Takayama, K ;
Obata, Y .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2001, 24 (09) :1044-1048
[10]
Determination of eprosartan in human plasma and urine by LC/MS/MS [J].
Li, Xue-Ning ;
Xu, Hong-Rong ;
Chen, Wei-Li ;
Liu, Gang-Yi ;
Chu, Nan-Nan ;
Yu, Chen .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 853 (1-2) :47-53